分子靶向治疗在EGFR突变肺鳞癌中的研究进展OA北大核心CSTPCDMEDLINE

Non-small cell lung cancer(NSCLC)is a prevalent tumour type in our country,with lung squamous car-cinoma being a commonly observed NSCLC subtype besides lung adenocarcinoma.Epidermal growth factor receptor(EGFR)is a significant driver gene in lung cancer,and EGFR mutation frequency is considerably lower in lung squamous carcinoma in comparison to lung adenocarcinoma.Although targeted therapy against EGFR has demonstrated significant advancements in lung adenocarcinoma,while progress in lung squamous carcinoma has been relatively sluggish.This paper reviews recent stud-ies on molecular targeted therapy for EGFR-mutated lung squamous carcinoma and summarises the efficacy of EGFR-tyrosine kinase inhibitors(TKIs)in treating squamous carcinoma of the lung,in order to provide a reference for treating patients with EGFR-mutated squamous carcinoma of the lung.